<DOC>
	<DOCNO>NCT01766778</DOCNO>
	<brief_summary>The purpose study observe change HbA1c time baseline month 12 . The ultimate goal study provide local reference value physicians &amp; patient future consider initiate Vildagliptin take balance efficacy , compliance , risk factor , convenience medication cost .</brief_summary>
	<brief_title>Early add-on Vildagliptin Patients With Type 2 Diabetes Inadequately Controlled Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Male Female age â‰¥18 Visit 1 2 . Type 2 diabetes mellitus ( T2DM ) patient maximum tolerate dose Metformin 3 month 3 . HbA1c ( glycosylated hemoglobin ) Visit 1 great 7.0 % 4 . With near document record HbA1c Visit 1 great 7.0 % patient reach his/her maximum tolerate dose Metformin Key 1 . Patients hepatic impairment , include patient pretreatment alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 X upper limit normal Visit 1 2 . Patients moderate severe renal impairment endstagerenaldisease ( ESRD ) haemodialysis time enrolment 3 . Patients hereditary problem galactose intolerance , Lapp lactose deficiency glucosegalactose malabsorption 4 . Pregnant woman breastfeed woman time enrolment 5 . Use insulin oral antidiabetic drug ( OAD ) apart Metformin past T2DM treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>type-2 diabetes mellitus , inadequately control Metformin</keyword>
</DOC>